Erwinase Master Treatment Protocol (EMTP)
Sponsor: Fisher Bioservices
Listed as NCT00590915, this observational or N/A phase trial focuses on Acute Lymphoid Leukemia and Leukemia, Acute Lymphoblastic and remains ongoing. Sponsored by Fisher Bioservices, it has been updated 8 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
No Longer Available
-
Sep 2024 — Feb 2026 [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Jan 2021 — Jul 2024 [monthly]
No Longer Available
-
Jun 2018 — Jan 2021 [monthly]
No Longer Available
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
No Longer Available
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
No Longer Available NA
-
Jan 2017 — Feb 2017 [monthly]
No Longer Available NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fisher Bioservices
- Jazz Pharmaceuticals
- Phoenix Children's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.